StockNews.com Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Hold

LeMaitre Vascular (NASDAQ:LMATGet Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other equities analysts have also recently issued reports on the company. Barrington Research lifted their price target on LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research report on Wednesday, February 28th. KeyCorp began coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They issued a “sector weight” rating for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $68.20.

Check Out Our Latest Report on LeMaitre Vascular

LeMaitre Vascular Trading Down 0.6 %

Shares of NASDAQ:LMAT opened at $65.99 on Friday. LeMaitre Vascular has a 12-month low of $44.27 and a 12-month high of $74.64. The firm has a market cap of $1.47 billion, a PE ratio of 49.25, a price-to-earnings-growth ratio of 2.86 and a beta of 0.87. The company has a fifty day simple moving average of $63.48 and a 200 day simple moving average of $57.03.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The company had revenue of $48.90 million during the quarter, compared to analyst estimates of $49.01 million. During the same quarter last year, the firm earned $0.25 EPS. The business’s revenue was up 19.3% on a year-over-year basis. As a group, equities research analysts forecast that LeMaitre Vascular will post 1.66 EPS for the current fiscal year.

Insider Activity at LeMaitre Vascular

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the sale, the director now directly owns 5,309 shares in the company, valued at approximately $358,357.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director John A. Roush sold 7,500 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the transaction, the director now owns 2,278 shares in the company, valued at $157,182. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the sale, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 114,036 shares of company stock worth $7,873,749. 12.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. Comerica Bank acquired a new stake in shares of LeMaitre Vascular during the second quarter worth $114,400,000. Mesirow Institutional Investment Management Inc. bought a new stake in LeMaitre Vascular in the fourth quarter valued at approximately $8,837,000. Congress Asset Management Co. MA boosted its position in LeMaitre Vascular by 36.3% during the third quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock worth $27,696,000 after purchasing an additional 135,266 shares during the period. Vanguard Group Inc. boosted its holdings in shares of LeMaitre Vascular by 10.1% during the 1st quarter. Vanguard Group Inc. now owns 1,426,235 shares of the medical instruments supplier’s stock worth $66,278,000 after buying an additional 130,881 shares during the period. Finally, Ranger Investment Management L.P. grew its position in shares of LeMaitre Vascular by 15.8% in the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after purchasing an additional 122,601 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Stories

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.